论文部分内容阅读
目的：研究ＣＡ１５－３对乳腺疾病诊断及治疗的临床意义。方法：术前术后、化疗前、后分别抽取周围静脉血，酶联免疫吸附法（ＥＬＩＳＡ）测定ＣＡ１５－３水平。结果：乳腺癌ＣＡ１５－３阳性率为３６．８％，Ⅰ、Ⅱ、Ⅲ和Ⅳ期病变术前阳性率分别为１１．１％、２６．１％、４６．１％、１００％，复发和有远处转移病人阳性率为７５％，良性病变ＣＡ１５－３阳性率为１６．３％。ＣＡ１５－３阳性乳腺癌病人手术后或化疗后短期内ＣＡ１５－３水平即有不同程度下降。结论：ＣＡ１５－３是监测乳腺癌术后早期复发和疗效判断的一项有效指标。
Objective: To study the clinical significance of CA15-3 in the diagnosis and treatment of breast diseases. Methods: Peripheral venous blood was collected before and after surgery, before and after chemotherapy, and CA15-3 levels were measured by enzyme-linked immunosorbent assay (ELISA). Results: The positive rate of CA15-3 in breast cancer was 36.8%. The preoperative positive rates of stage I, II, III, and IV were 11.1%, 26.1%, 46.1%, and 100%, respectively. The positive rate of patients with distant metastasis was 75%, and the positive rate of CA15-3 in benign lesions was 16.3%. The CA15-3 levels of CA15-3 positive breast cancer patients decreased to varying degrees after surgery or shortly after chemotherapy. Conclusion: CA15-3 is an effective index to monitor early postoperative recurrence and efficacy of breast cancer.